Barclays maintains Zimmer Biomet Holdings at Equal-Weight, raises price target to $115 from $100
Barclays kept Zimmer Biomet Holdings at Equal-Weight, raising its price target to $115 from $100, a 15% increase. This implies an 8.9% upside from the Nov 6 close of $105.59. Recent analyst targets range from $107 to $130.
How this was made

The 30-second read
Why it matters
The upward revision may attract short-term buying interest.
Market read
Analyst target raise could influence ZBH's near-term price action.
What to watch
No new operational data; price target change alone may not drive sustained move.
Background
Barclays' analyst note updates price target based on recent assessments.
Ticker impact
Barclays raised its price target on Zimmer Biomet Holdings to $115 from $100.
likely upward pressure as investors price in the higher target
Target raise reflects improved outlook; market may bid the stock higher.
Market effects
May lift sentiment in the medical devices sector.
Limited to US equities market.
Low global impact.
Counterpoint
Target raise could be premature if underlying earnings miss expectations.
Key entities
- companyZimmer Biomet Holdings
Medical device manufacturer.
- analystBarclays
Investment bank providing the price target revision.

